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ABSTRACT
Traditional functional assays such as hemagglutination inhibition (HAI) and microneutralization (MN) assays have been routinely used for assessing the vaccine response, since
influenza vaccine has been administered in people (1940). Such assays are not always predictive
regarding the protection conferred by the influenza vaccine and are not able to monitor
neutralization related to stem region of influenza hemagglutinin responsible for virus membrane
fusion in the endosomes. In order to study Influenza vaccine response in a more biomimetic
manner and overcome the deficiencies of the traditional functional assays, we developed a
fluorescent membrane fusion assay (fMF). The assay uses viruses labeled with Octadecyl
Rhodmaine B Chloride (R18) to monitor two major neutralization pathways: blocking the
attachment of virus to the target cells and blocking of virus membrane fusion in the endosomes.
The latter was tested using endosomal acidification inhibitor Bafilomycin a1 which blocked
membrane fusion by 85%. Specificity of the assay was tested using two different subtypes of
viruses H1N1 (A/Puerto Rico/8/1934 and A/Brisbane/59/2007), and H3N2 virus (A/Aichi/68)
with their respective subtype specific stem specific monoclonal antibodies: M145, Aca-1, Aca-2
(H1N1 specific) and Aca-3 (H3N2 specific). Subtype specific mAbs blocked membrane fusion,
while a mismatch in virus subtype and the mAb resulted in lack of blocking. We also studied the
effect of H1N1 head specific mAb Aca-4, which not only blocked attachment of the virus, but
also demonstrated blocking of membrane fusion. Results were validated by testing pre- and postsera from 2009 seasonal Influenza vaccination and to show that at higher Ab concentration the
majority of virus (85%) was blocked from attaching cells, but at lower Ab concentration, where
attachment could not be prevented, blocking of membrane fusion was still in effect - up to 50%.
iii

Sera screening experiments showed that sera antibodies work beyond just blocking attachment.
They also may neutralize the already attached virus by blocking fusion of the viral membrane in
the endosomes. The assay has the capacity to monitor blocking of attachment and fusion in a
single run. Therefore, it is more representative regarding the natural process of infection and the
corresponding neutralization pathways. The assay is unique in terms of assessing stem specific
antibodies; stem specific response and its measurement are relevant for the advancement of a
universal influenza vaccine.
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INTRODUCTION
Influenza is a respiratory disease caused by influenza virus. The virus causes seasonal
outbreaks every year and pandemics are caused sporadically. The burden of disease is
tremendous, worldwide every year there are hundreds of millions of influenza cases, with 3 to 5
million cases of severe illnesses and 250,000 to 500,000 people die from the illness[1]. The
disease readily attacks and spreads easily in immunocompromised individuals such as older
population, younger children and people with ongoing medical conditions[2].
Influenza vaccine is the most widespread method of protection against influenza virus.
Inactivated seasonal Influenza vaccines came into practice in 1940’s followed by live attenuated
influenza vaccine in 1960’s[3]. The response to the vaccine is mounted in form of serum
antibodies. These antibodies are directed mainly towards the globular head of virus’s surface
glycoprotein Hemagglutinin (HA). In order to escape the immune response of its host, the virus
frequently mutates epitopes on the head region of its HA[4]. For this reason, influenza vaccines
need to be reformulated every year, based on the currently circulating strain recommendations
made by WHO’s influenza surveillance programs[5]. This approach to formulating vaccines is
very well established and saves human lives and resources every year. On the other hand, this
process of influenza vaccine production costs $1-2 billion every year. In addition to the high cost
associated with yearly vaccine reformulation, pandemic strains are unexpected, difficult to
predict, and seasonal strain matching with vaccine is not always accurate[6]. In the wake of these
issues, the influenza vaccines portfolio is evolving.
There have been many new advances made to existing influenza vaccine such as using
higher dose of HA to generate a better antibody response for elderly population. Recently,
1

quadrivalent flu vaccine was approved to provide broader protection as it contains two A strains
(H1N1 and H3N2) and two B strains, to cover both most probably expected B lineages in the
vaccine. In addition, modifications such as intradermal vaccine, using oil in water emulsion
adjuvant have also been made to existing licensed vaccine[7]. In order to alleviate the need for
reformulating vaccine every year, current scientific efforts are enthusiastically directed towards
development of a Universal influenza vaccine. The universal vaccine approach is based on
targeting conserved epitopes on influenza virus proteins such as stem region of HA,
nucleoprotein and M2 channel protein[8].
The serum antibody response towards globular head of HA is accepted as primary
correlate of protection for influenza vaccine. This antihead response is universally tested by
hemagglutination inhibition (HI, or HAI) assay. HI assay is based upon agglutinating ability of
influenza virus towards red blood cells. In presence of HA head specific antibodies the
agglutination of RBCs by influenza virus is inhibited. An HI titer 40 is generally recognized as
measure of 50% protection[9]. With the evolving influenza vaccine portfolio the correlates of
protection are changing[7]. For example, with universal flu vaccine being based mainly on stem
region of HA, measuring stem specific response is becoming crucial and the stem specific
response has become a new correlate of protection.
The HA protein on influenza virus is a trimeric molecule consisting of three identical HA
molecules. The protein appears as spikes on the surface of influenza virus envelope. The HA
spike is divided into three domains: globular head responsible for virus attachment to host cells,
stem domain which is responsible for membrane fusion in endosomes of host cells and a
transmembrane domain which holds the HA trimer into viral membrane[10]. The globular head
2

is the most antigenic and variable region. The epitopes on head are 98% variable among different
subtypes and strains of influenza virus. On the other hand, the stem region has epitopes which
are more than 98% conserved amongst different influenza viruses. The highly conserved
structure of HA stem amongst various subtypes of influenza virus make it a very attractive target
for developing universal flu vaccine[6]. Scientists have shown that natural infection and seasonal
vaccine are able to generate stem specific antibodies in humans. Many stem specific monoclonal
antibodies (mAbs) have been isolated from humans that are able to neutralize a wide range of
influenza viruses of different subtypes and strains[11-13]. Now the efforts are being made to
boost up the stem specific antibody response after vaccination. Approaches towards such
vaccines include stem based vaccine constructs without globular head[14] and chimeric
hemagglutinin based vaccine constructs[15]. There are studies that have shown that stem based
vaccine constructs are able to generate heterosubtypic neutralizing antibodies in animal
studies[15, 16]. Although there is a definitive amount of progress that has been made in direction
of stem based vaccines, still there are few substantive methods to assess general anti-virus
immune response, and no universally accepted laboratory methods that can be used to measure
stem specific response. Therefore, there is need to develop a method that can measure this new
correlate of protection i.e., functional effect of stem specific antibodies.
On another note, a study in neonatal pigs showed that mismatch between vaccine and
infecting virus has been reported to generate stem specific antibodies that increase endosomal
membrane fusion, thereby increasing the morbidity of the disease[17]. Therefore, it is important
to monitor membrane fusion and stem specific response not just in context of universal flu
vaccine, but also to test the safety of vaccine that generates stem specific antibodies.
3

Summary Of Thesis:
The functional assays currently used for measuring antibody response generated by
influenza vaccine provide only fragmentary information about the mode of protection of the
antibodies. For example, HI assay only measures titers in terms of blocking of attachment of
virus to RBCs. MN assay cannot differentiate between blocking of attachment and blocking of
membrane fusion by neutralizing antibodies. The aim of this project was to develop an assay that
can assess functional characteristics and mechanisms of protection provided by influenza vaccine
generated antibodies, i.e. blocking of virus attachment to the cells (pre-attachment neutralization
pathway) and blocking fusion of viral membrane in the cell endosomes (major element of postattachment neutralization).
Influenza virus attaches to its target cells by binding through globular head of HA trimer on its
surface to the Sialic acid receptors present on glycolipids or glycoproteins of cellular
membranes. Once the virus is attached to target cells, it gets internalized into endosomes due to
cycling of cellular membranes. In the endosomes, the acidic environment splits apart the HA
trimer, opening up the globular head and exposing the stem region. The stem region of the
protein then turns itself inside out and exposes its hidden fusion peptide at its N terminus. Fusion
peptide then inserts itself into endosomal membrane, bringing endosomal membrane and viral
membrane closer together and fuse. The fusion of two membranes leads to stalk pore formation
and release of viral RNA in cellular cytoplasm through the pore[18]. fMF assay monitors the
process of virus attachment to the cells and endosomal membrane fusion by kinetically following
interaction of target cells (vero cells) with Octadecyl Rhodamine B Chloride (R18) dye labeled
Influenza virus.
4

Use of R18 dequenching for studying kinetics of fusion between biological membranes
was first described by Hoekstra, D. et al in 1984[19]. Since then it has become a widely used
label for studying fusion kinetics. R18 dye is lipophilic in nature; it enters the envelope of the
virus and remains in the envelope in self quenched state. When the labeled virus fuses with
another membrane such as host cell endosomal membrane, the dye gets diluted and becomes
fluorescent. This increase in fluorescence due to dye dilution in membrane is indicative of viral
endosomal membrane fusion[20].
The ability of fMF assay to monitor membrane fusion was tested using Bafilomycin a1 a
specific endosomal acidification inhibitor. As Influenza needs acidic environment for membrane
fusion to occur, the inhibitor blocked membrane fusion by 85%. Specificity of the assay was
tested

using

two

different

subtypes

viruses

H1N1

(A/Puerto

Rico/8/1934

and

A/Brisbane/59/2007), and H3N2 virus (A/Aichi/68) with their respective subtype specific stem
specific monoclonal antibodies. As stem region on HA is key participant in membrane fusion,
stem specific mAbs effectively blocked membrane fusion. In addition, only subtype specific
mAbs were able to block membrane fusion. There was no cross neutralization between different
subtypes and their mAbs. In order to study effect of antibodies on attachment of virus, one H1N1
head specific mAb was also included in the study. The head specific antibody blocked both
attachment of the virus and membrane fusion. The study was concluded by testing pre- and postsera from 2009 seasonal Influenza vaccination. The sera showed characteristics similar to head
specific antibodies, at lower sera dilution (higher Ab concentration) majority of virus (85%) was
blocked from attaching cells, but at higher sera dilution (lower Ab concentration) where
attachment could not be prevented, blocking of membrane fusion was still in effect - up to 50%.
5

In conclusion fMF assay is a method that is able to monitor interaction of influenza virus and its
target cells in a biomimetic manner. It is an assay that can functionally characterize response of
post vaccination sera into two major neutralization pathways: blocking of attachment of virus
and blocking of viral endosomal membrane fusion. By monitoring both the pathways in the same
run the assay is able to demonstrate the interplay of these two neutralization pathways in
presence of antibodies. With conventional assays only being able to either monitor blocking of
attachment or altogether neutralization, fMF assay opens the door for monitoring an important
new correlate of protection, the membrane fusion. Monitoring membrane fusion is very
important in context of universal flu vaccine and pandemic threats.
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METHODOLOGY
Labeling Influenza Virus
Influenza viruses PR8 (A/Puerto Rico/8/1934 H1N1), X-31(A/Aichi/68 H3N2) (Charles
River laboratory) and Brisbane H1N1 (A/Brisbane/59/2007 H1N1) (Sanofi Pasteur) were labeled
with Octadecyl Rhodamine B chloride dye (R18) (Life Technologies). Viral protein content was
determined using BCA kit (Pierce Technology) using high grade Bovine Serum Albumin (BSA;
Sigma-Aldrich) as internal standard. 100µg of viral protein was labeled with 5µg R18 while
vortexing. Labeled virus was then incubated at room temperature for one hour on orbital shaker.
The labeled virus was stored at 4ºC. The virus was used within one week after labeling.
Vero Cell Culture
Vero cells were obtained from ATCC, USA. Cells were grown in Iscove’s Modified
Dulbecco’s Medium (IMDM, ATCC) containing 4mM L-glutamine, 4500mg/L glucose and
1500mg/L sodium bicarbonate with fetal bovine serum (10%) and 1% penicillin-streptomycinglutamine (Life Technologies). Cells were maintained at 37ºC, 5% CO2 in a humidified
incubator.
Fluorescent Membrane Fusion Assay
1µg of labeled virus was incubated with 500,000 vero cells on ice in BSA buffer ,1%
Bovine serum albumin (Sigma-Aldrich) in Dulbecco phosphate buffered saline (DPBS) (Lonza)
for 45 minutes. The cells with virus were then washed two times with cold BSA buffer. The cells
were then resuspended in BSA buffer pre-warmed at 37ºC. The kinetics of interaction of virus
7

with the cells was then read on ELISA plate reader (Biotek instruments) in fluorescence mode.
The excitation wavelength of 530 nm was used and emission at 590 nm was observed. The
kinetic study was carried out for 30 minutes with an interval of 10 to 20 seconds. At the end of
kinetics study, 10µl of 10% Triton X (Invitrogen) was added to cells and fluorescence generated
after addition of Triton X was recorded.
In order to assess the ability of fMF assay to monitor endosomal fusion, an endosomal
acidification inhibitor Bafilomycin a1 (Sigma Aldrich) was used. For the experiments carried out
in presence of Bafilomycin a1, the BSA buffer in fMF assay was replaced with a 100 nM
solution of Bafilomycin a1 prepared in BSA buffer.
In order to assess the subtype specificity of fMF assay, a group of subtype specific mAbs
were tested in the fMF assay. Table 1 shows the list of all the antibodies used in this study.
For the experiments carried out in presence of monoclonal antibodies (mAbs), the virus
was incubated overnight at 4°C with the mAbs diluted at appropriate concentration in BSA
buffer. The viruses preincubated with mAbs were then incubated with cells and the fMF assay
was carried out in the same way as described above.
Table 1: List of monoclonal antibodies
mAb

Epitope specificity

M145
Aca-1

Source
Takara Bio Inc

H1N1 stem

Aca-2

Sanofi Pasteur

Aca-3

H3N2 stem

Aca-4

H1N1 head
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Cambridge Campus

Pre and post vaccination sera obtained from human donors who received 2008 influenza
vaccine were analyzed using fMF assay. The donor sera were diluted appropriately in BSA
buffer. The viruses were preincubated with diluted sera for one hour at 4°C. The viruses were
then incubated with cells and the fMF assay was carried out in the same way as described above.
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RESULTS
Scheme Of Study
The study was divided into five stages, and their deliverables are described below. Figure
1 shows the breakdown of these stages.
Stage 1: Show that the presence of endosomal acidification blocker blocks membrane fusion.
Stage 2: Test the effect of presence of stem specific mAbs on membrane fusion. Demonstrate
the specificity of fMF assay by testing two different subtypes of viruses PR8 H1N1 and X-31
H3N2 with their subtype specific mAbs.
Stage 3: Transition to a vaccine strain influenza virus, Brisbane H1N1. Use fMF assay to study
blocking of membrane fusion of Brisbane H1N1 virus in presence of stem specific antibodies
Stage 4: Use fMF assay to study blocking of attachment of Brisbane H1N1 virus in presence of
head specific antibodies
Stage 5: Use fMF assay to study effect of presence of pre and post vaccination on attachment
and membrane fusion of Brisbane H1N1 virus.
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Figure 1 Scheme of study
Effect of Blocking Membrane Fusion on fMF Read Out
In order to assess whether fMF assay that is based on dequenching of R18 fluorescent
probe can monitor endosomal processing of influenza virus, an endosomal acidification blocker
Bafilomycin a1 was used. Bafilomycin a1 is an H+ VATPases blocker. V-ATPase is a proton
pump which is responsible for pumping protons into endosomes and acidifying the endosomal
compartments.
For fusing with endosomal membrane, the influenza, virus needs presence of acidic
environment in the endosomes. Therefore, presence of bafilomycin a1 should have a blocking
effect on membrane fusion.
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Figure 2 Endosome acidification inhibitor blocks R18 dequenching
A: R18 dequenching %, relative to total fluorescence.
B: Fusion at 20 minutes, relative to No Treatment.
C: Total virus attachment relative to No Treatment, determined by measuring total
fluorescence after adding detergent that disperses membranes and releases the dye.
Figure 2 shows that in comparison to no treatment, using endosomal acidification blocker
Bafilomycin A1 reduced the relative fusion by ~ 85% without affecting attachment of virus
to cells. This shows that the dequenching of R18 observed in our experiments is indicative of
endosomal fusion of influenza virus. We also observed a lag of ~ 7 minutes before the
beginning of dequenching, this lag possibly corresponds to endocytosis of virus by the cells.
This experiment was a first step to show that the fMF assay that uses R18 dequenching can
address influenza virus endocytosis and endosomal fusion.
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Effect Of Stem Specific Antibodies on Membrane Fusion Of Two Different Subtypes Of
Influenza Viruses
In order to prove that fMF assay can represent endosomal membrane fusion, stem
specific mAbs were used to test the system. Since stem region of hemagglutinin plays an
important role in the membrane fusion process, stem specific antibodies should block membrane
fusion.
Two viruses belonging to two different subtypes, PR8 (H1N1) and X-31 (H3N2) were
tested with subtype specific stem related mAbs in order to to demonstrate the ability of fMF
assay to differentiate between different subtypes of viruses and their respective antibodies.

Figure 3 H1N1 specific mAb M145 blocks fusion of PR8 (H1N1) virus
Figure 3 shows effect of stem specific murine mAb M145 on membrane fusion and
attachment of PR8 virus. M145 is known to be a H1N1 stem specific mAb and it blocked fusion
of a H1N1 virus. 50% titer for M145 with PR8 virus was 2.6 µg/ml. M145 blocked fusion of the
virus without affecting its attachment to vero cells. Stem region of the HA plays important role
in fusion of viral and endosomal membranes. Blocking of fusion in presence of stem specific
mAb shows that fMF assay is indicative of endosomal fusion process. In most of the following
experiments, M145 was used as a positive control at 10 mg/ml.
13

Figure 4 H1N1 specific mAbs Aca-1 and Aca-2 block fusion of PR8 (H1N1) virus
A and B: Effect of mAb Aca-1 on blocking membrane fusion and attachment of PR8 virus.
C and D: Effect of mAb Aca-2 on blocking membrane fusion and attachment of PR8 virus.
Figure 4 shows effect of human derived mAbs Aca-1 and Aca-2 on membrane fusion and
attachment of PR8 virus. Both antibodies blocked membrane fusion in dose dependent manner
without affecting the attachment of virus to vero cells. Aca-1 and Aca-2 are H1N1 stem region
specific mAbs, their blocking of membrane fusion of an H1N1 virus without affecting its
attachments shows that fMF assay is able to observe endosomal membrane fusion in fMF assay.
The 50% titer of the Aca-1 and Aca-2 mAb’s were 0.2 and 0.5 µg/ml respectively.
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Figure 5 H3N2 specific mAb Aca-3 does not block fusion of PR8 (H1N1) virus

Figure 6 H3N2 specific mAb Aca-3 blocks fusion of X-31 (H3N2) virus
Figure 5 shows that an H3N2 stem specific mAb Aca-3 does not block membrane fusion
of PR8, an H1N1 virus. The experiment was carried out to demonstrate the specificity of fMF
assay. The membrane fusion of H1N1 virus can only be blocked by a H1N1 specific mAb, not
with a H3N2 specific mAb.
Figure 6 shows that Aca-3 which is a H3N2 stem specific mAb blocks membrane fusion
of X-31 H3N2 virus in dose dependent manner. This corroborates the capacity of fMF assay to
differentiate between H1N1 and H3N2 specific antibodies and between corresponding viruses.
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At 20 µg/ml Aca-3 showed a slight and possibly nonspecific effect on attachment as well, this
could be due to high Ab concentration.

Figure 7 H1N1 specific mAbs do not block fusion of X-31 (H3N2) virus
A and B: Effect of mAb M145 on blocking membrane fusion and attachment of X-31 virus.
C and D: Effect of mAb Aca-1 on blocking membrane fusion and attachment of X-31 virus
E and F: Effect of mAb Aca-2 on blocking membrane fusion and attachment of X-31 virus
16

Figure 7 shows the effect of H1N1 stem specific antibodies on membrane fusion and
attachment of X-31 H3N2 virus. H1N1 stem specific mAbs M145, Aca-1 and Aca-2 were not
able to block membrane fusion and attachment of X-31 virus to vero cells. This set of
experiments served as negative control for H3N2 subtype of virus and were carried to
demonstrate specificity of fMF assay.
The series of experiments with mAbs showed that membrane fusion can be blocked by
stem specific mAbs. This further supported capacity of fMF assay to monitor membrane fusion
and its blocking. The subtype specific antibodies showed that fusion of influenza viruses of two
different subtypes (PR8 and X-31) could only be blocked by mAbs specific to their serotypes.
These results show that fMF assay is very specific and able to differentiate between two very
distinct subtypes of influenza viruses.
Applicability Of fMF Assay To A Seasonal Influenza Strain A/Brisbane/59/2007 H1N1
In order to achieve the main objective of this project “Use fMF assay to test vaccine
generated Abs in biomimetic manner”, a more recent vaccine strain Brisbane H1N1 was tested in
the fMF experiments.
Table 2 Summary of the fMF assay titers using Brisbane H1N1 virus and stem specific mAbs
mAb

Epitope specificity

Aca-1

Titer µg/ml
1.25

H1N1 stem
Aca-2
Aca-3

1.25
H3N2 stem

17

Subtype mismatch hence does
not block fusion of H1N1
virus

Aca-1, Aca-2 and Aca-3 were used to test applicability of fMF assay to Brisbane H1N1
virus. Table 2 shows the summary of results from dose titration experiments of mAbs with
Brisbane H1N1 virus. H1N1 stem specific mAbs Aca-1 and Aca-2 were able to block fusion of
Brisbane H1N1 virus. Aca-3 which is H3N2 specific mAb did not have an effect on the fusion of
Brisbane H1N1 virus. This shows that vaccine specific strain Brisbane H1N1 virus performed
well in fMF assay.
An H1N1 head specific mAb Aca-4 was used in order to test the capacity of fMF assay to
monitor blocking virus attachment. Brisbane H1N1 virus was incubated with different dilutions
of Aca-4 and the effect of presence of Aca-4 antibody on virus attachment and membrane fusion
was monitored.

Figure 8 Effect of head specific mAb Aca-4 on attachment and membrane fusion of Brisbane
H1N1 virus
Figure 8 shows that at a higher antibody concentration 1µg/ml head specific mAb Aca-4
blocks attachment of the virus to cells by 85%. For the remaining 15% of the attached virus, 70%
of fusion is blocked. Fusion % for each condition was calculated using total fluorescence
generated by virus attached at that condition. Therefore, at 1 µg/ml, fusion blocking was
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calculated using fluorescence corresponding to ~15% virus attached. At a lower antibody
concentration 0.25 µg/ml, 50% fusion was blocked and there was no effect on attachment of
virus to the cells.
Blocking of fusion in presence of head specific mAb was an unexpected outcome.
However, there are some previous studies that have shown that head specific mAbs have
membrane fusion blocking effect[21, 22]. These studies have shown that mAbs directed towards
different antigenic sites on HA head are capable of post attachment neutralization and this post
attachment neutralization is accomplished by blocking membrane fusion.
Presence of head specific antibody Aca-4 blocked attachment of virus and membrane
fusion. fMF assay was able to detect both effects in a single run. Therefore, the assay was turned
to study effects on attachment and fusion of Brisbane H1N1 virus in presence of sera from
vaccinated donors.
FMF Assay To Monitor Blocking Of Fusion and Attachment Of Influenza Virus By Vaccine
Generated Antibodies In Donor Sera
The objective of this set of experiments was to test ability of fMF assay to screen preand post-vaccination human sera for their capacity to block fusion and attachment, in a single
run. Pre- and post-vaccination sera of four human donors immunized with 2009 seasonal flu
vaccine was run through the fusion assay using Brisbane H1N1 virus. This strain of virus was
used since 2009 seasonal flu vaccine contained Brisbane H1N1 virus antigen.

19

Figure 9 Monitoring the capacity of pre and post vaccination sera to block attachment and fusion
20

Figure 9 shows fMF assay data from four donors. Pre and post vaccination sera from four
human donors were run through fMF assay. Donor #1142 and donor #981 were high responders,
the other two donors, #654 and #821 were low responders. High responder sera showed blocking
profile similar to head specific mAb Aca-4. At higher sera concentration, 80-50% virus was
blocked from attaching cells. For the remaining attached 20-50% of the virus, fusion was
blocked by 50-80%. At lower sera concentration, when blocking of attachment was no longer
effective, blocking of fusion was still in effect up to 50%. A low responder post vaccination
serum, donor #821, showed insignificant capability of blocking of virus attachment. On the other
hand, the same donor showed an effective 50% blocking of membrane fusion. The blocking of
membrane fusion in the absence of blocking of attachment shows the value of fMF assay. The
donors which appear to be nonresponder in attachment blocking tests such as HAI can show
response in a post attachment step such as blocking membrane fusion.

Figure 10 Correlation of fMF assay titers and HAI titers
Titers from fMF assay were compared with titers from classical HAI assay. Figure 10
shows that blocking of attachment and membrane fusion observed in the fMF assay positively
correlated with the data of classical HAI assay.
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In the same time, blocking of membrane fusion has been observed for a serum which
showed insignificant capacity to block attachment (#821), which may signify importance of
neutralization via membrane fusion blocking pathway.

22

DISCUSSION
fMF assay was developed to meet two unmet needs of influenza vaccine assessment, first
to assess a new correlate of protection of influenza vaccine i.e. the stem specific response and
second to simultaneously analyze immune sera for pre attachment neutralizing and post
attachment neutralization antibodies. The method ties together the two major neutralization
pathways: blocking attachment of virus to host cells and blocking of membrane fusion of the
internalized virus in the endosomes.
fMF assay was tested for its ability to monitor membrane fusion by using Bafilomycin
a1, a very specific endosomal acidification blocker. By demonstrating that Bafilomycin a1blocks
85% of membrane fusion without affecting the attachment of virus, the fMF assay was shown to
be representative of endosomal fusion process. The specificity of the assay and its capacity to
measure stem specific response was tested by using subtype specific stem related antibodies. It
was shown by using two subtypes of viruses H1N1 and H3N2 and their respective stem specific
antibodies, that fMF assay is able to monitor blocking of membrane fusion in presence of stem
specific antibodies. The assay is also able to distinguish between two distinct subtypes of viruses
H1N1 and H3N2, as their membrane fusion was blocked only in presence of their subtype
specific antibodies. Experiments with stem specific antibodies further corroborated the capacity
of fMF assay to measure stem specific response and the subtype specificity of the assay.
A head specific mAb was used to study its effect on attachment and fusion of Brisbane
H1N1 virus. Expected outcome of this experiment was that head specific mAb should block
attachment of Brisbane H1N1 virus and fusion should remain unaffected. On the contrary, the
head specific antibody not only blocked attachment of virus, it also had a significant effect on
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blocking membrane fusion. Similar results with head specific antibodies have been observed in
some previous studies where they have shown that head specific mAbs neutralize influenza virus
by preferentially blocking attachment of virus. However, when at 50% neutralization the
blocking of virus attachment was minimal. Therefore, there was some other mechanism that
blocked infectivity of virus. It was shown in the same study that there is a very strong correlation
between infectivity and membrane fusion. Therefore, it was proposed that head specific
antibodies along with blocking attachment can also block membrane fusion by either sterically
interfering with fusion process or by crosslinking two adjacent HA trimers[21].
After substantiating fMF assay with mAbs, sera screening experiments were performed.
fMF assay was able to detect blocking of both fusion and attachment in the presence of immune
sera in a single run. The high responder sera showed characteristics similar to a head specific
mAb. At higher sera concentration, blocking of attachment was most effective, i.e 85% of virus
was prohibited from attaching the cells. At lower sera concentration when blocking of
attachment was not effective, the sera were still able to block post attachment membrane fusion
of virus. Sera screening experiments showed that sera antibodies work beyond just blocking
attachment. They may also neutralize the already attached virus by blocking fusion of the viral
membrane in the endosomes. This could mean that in order to achieve protection from influenza,
lesser quantity of antibodies may be needed than what can be required based on HAI data alone.
Therefore, for in vitro vaccine testing, blocking of membrane fusion needs to be taken into
consideration as a very important neutralization pathway.
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The assay has demonstrated ability to monitor blocking of attachment and fusion in a
single run. Therefore, it is more representative regarding the natural process of infection and the
corresponding neutralization pathways.
For future applications, fMF assay can be developed for other enveloped viruses, such as
dengue and filoviruses to study the neutralization pathways and functional characteristics of
antibodies generated by vaccine candidates. Other cell types other, such as monocytes, dendritic
cells or NK cells can also be used in fMF assay to study effect of antibodies on protection of
different types of target cells.

25

REFERENCES
1.
2.
3.
4.

5.
6.
7.
8.
9.

10.

11.
12.
13.
14.
15.

16.

17.

18.

WHO Influenza (Seasonal) Fact sheet N°211. 2014; Available from:
http://www.who.int/mediacentre/factsheets/fs211/en/.
Clark, N.M. and J.P. Lynch, 3rd, Influenza: epidemiology, clinical features, therapy, and
prevention. Semin Respir Crit Care Med, 2011. 32(4): p. 373-92.
Osterhaus, A., R. Fouchier, and G. Rimmelzwaan, Towards universal influenza vaccines?
Vol. 366. 2011. 2766-2773.
DiLillo, D.J., et al., Broadly neutralizing hemagglutinin stalk-specific antibodies require
Fc[gamma]R interactions for protection against influenza virus in vivo. Nat Med, 2014.
20(2): p. 143-151.
Salzberg, S., The contents of the syringe. Nature, 2008. 454(7201): p. 160-161.
Nabel, G.J. and A.S. Fauci, Induction of unnatural immunity: prospects for a broadly
protective universal influenza vaccine. Nat Med, 2010. 16(12): p. 1389-1391.
Reber, A. and J. Katz, Immunological assessment of influenza vaccines and immune
correlates of protection. Expert Review of Vaccines, 2013. 12(5): p. 519-536.
Gottlieb, T. and T. Ben-Yedidia, Epitope-based approaches to a universal influenza
vaccine. Journal of Autoimmunity, 2014. 54(0): p. 15-20.
Black, S., et al., Hemagglutination Inhibition Antibody Titers as a Correlate of
Protection for Inactivated Influenza Vaccines in Children. The Pediatric Infectious
Disease Journal, 2011. 30(12): p. 1081-1085 10.1097/INF.0b013e3182367662.
Skehel, J.J. and D.C. Wiley, RECEPTOR BINDING AND MEMBRANE FUSION IN
VIRUS ENTRY: The Influenza Hemagglutinin. Annual Review of Biochemistry, 2000.
69(1): p. 531-569.
Ekiert, D.C., et al., Antibody Recognition of a Highly Conserved Influenza Virus Epitope.
Science, 2009. 324(5924): p. 246-251.
Sui, J., et al., Structural and functional bases for broad-spectrum neutralization of avian
and human influenza A viruses. Nat Struct Mol Biol, 2009. 16(3): p. 265-273.
Ekiert, D.C., et al., A Highly Conserved Neutralizing Epitope on Group 2 Influenza A
Viruses. Science, 2011. 333(6044): p. 843-850.
Steel, J., et al., Influenza virus vaccine based on the conserved hemagglutinin stalk
domain. MBio, 2010. 1(1): p. e00018-10.
Krammer, F., et al., Chimeric hemagglutinin influenza virus vaccine constructs elicit
broadly protective stalk-specific antibodies. Journal of virology, 2013. 87(12): p. 65426550.
Wang, T.T., et al., Vaccination with a synthetic peptide from the influenza virus
hemagglutinin provides protection against distinct viral subtypes. Proceedings of the
National Academy of Sciences, 2010. 107(44): p. 18979-18984.
Khurana, S., et al., Vaccine-induced anti-HA2 antibodies promote virus fusion and
enhance influenza virus respiratory disease. Science translational medicine, 2013.
5(200): p. 200ra114-200ra114.
Harrison, S.C., Viral membrane fusion. Nat Struct Mol Biol, 2008. 15(7): p. 690-698.

26

19.
20.
21.

22.

Hoekstra, D., et al., Fluorescence method for measuring the kinetics of fusion between
biological membranes. Biochemistry, 1984. 23(24): p. 5675-5681.
Blumenthal, R., et al., Fluorescent lipid probes in the study of viral membrane fusion.
Chemistry and physics of lipids, 2002. 116(1): p. 39-55.
Edwards, M.J. and N.J. Dimmock, Two Influenza A Virus-Specific Fabs Neutralize by
Inhibiting Virus Attachment to Target Cells, While Neutralization by Their IgGs Is
Complex and Occurs Simultaneously through Fusion Inhibition and Attachment
Inhibition. Virology, 2000. 278(2): p. 423-435.
Edwards, M.J. and N.J. Dimmock, Hemagglutinin 1-Specific Immunoglobulin G and Fab
Molecules Mediate Postattachment Neutralization of Influenza A Virus by Inhibition of
an Early Fusion Event. Journal of Virology, 2001. 75(21): p. 10208-10218.

27

